About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Texas | 12,973 Studies Near You | Clareo Health

Clinical Trials LocationsTexas

Clinical Trials in Texas

Discover 12,973 clinical trials near Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 2821-2840 of 12,973 trials

COMPLETEDPhase 1/213 miles

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

NCT02052739

The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).

Super-refractory Status Epilepticus

Supernus Pharmaceuticals, Inc.25 participantsStarted Mar 2014

Birmingham, Alabama, United States • Sarasota, Florida, United States • Chicago, Illinois, United States +14 more locations

Active Not RecruitingPhase 243 miles

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

NCT06493578

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.

Non-segmental Vitiligo

Vyne Therapeutics Inc.200 participantsStarted Jun 2024

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Scottsdale, Arizona, United States +46 more locations

Find Trials by Condition in Texas

Breast Cancerin Texas Lung Cancerin Texas Prostate Cancerin Texas Colorectal Cancerin Texas Melanomain Texas Leukemiain Texas Lymphomain Texas Pancreatic Cancerin Texas Ovarian Cancerin Texas Brain Cancerin Texas Diabetesin Texas

Data from ClinicalTrials.govTerms

COMPLETEDPhase 355 miles

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

NCT05634811

This study is to understand if the study vaccine (called VLA15) is safe in healthy children. We are looking for children who: * are healthy * are age 5 through 17 * have not been diagnosed with any form of Lyme disease in the past * have not received any vaccines for Lyme disease in the past Lyme disease happens most often in children of this age. The study vaccine may be used potentially to help prevent Lyme disease. The goal of this study is to get more information about the safety of the study vaccine in this age group. Participants will be in this study for about 2 years. During that time, they will receive VLA15 or placebo (sterile saltwater solution) by a "shot" in the arm. We will compare experience of children receiving VLA15 to those receiving the placebo. Participants will not know whether they get VLA15 or placebo. Everyone participating in this study will: * get the shots in a clinic or in a hospital office * receive a total of 4 shots * receive the first 3 shots within 6 months * receive the last shot about 1 year afterwards * need to come to the trial site for 6 planned visits; 4 of these are vaccination visits and 2 are follow-up visits. We will contact you by phone 1 time every year during the study to monitor your experience. You may have extra visits if you experience a severe reaction after a vaccine dose.

Pfizer3,549 participantsStarted Dec 2022

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Guntersville, Alabama, United States +62 more locations

COMPLETEDNA55 miles

Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System

NCT03756558

This study evaluates the safety and effectiveness of the Cross-Seal vascular closure device in gaining post procedure hemostasis in subjects undergoing interventional procedures requiring an 8 to 18 french size introducer sheath.

Vascular Closure

Terumo Medical Corporation147 participantsStarted Aug 2019

Denver, Colorado, United States • Jacksonville, Florida, United States • Tampa, Florida, United States +17 more locations

TERMINATEDPhase 1/2126 miles

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

NCT04278144

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more

Bolt Biotherapeutics, Inc.175 participantsStarted Feb 2020

Palo Alto, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +18 more locations

Active Not RecruitingPhase 2126 miles

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06703021

Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.

ObesityOverweightChronic Weight Management

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics82 participantsStarted Dec 2024

Glendale, California, United States • Montclair, California, United States • Valparaiso, Indiana, United States +7 more locations

COMPLETEDPhase 1126 miles

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

NCT05718258

This is a parallel, Phase 1, four arm, open-label, single dose, multicenter study to evaluate the impact of hepatic impairment on venglustat exposure following treatment with venglustat. The purpose of this study is to assess the effect of mild, moderate, and severe hepatic impairment on PK, safety, and tolerability of venglustat compared with normal hepatic function in male and female participants aged 18 to 79 years. Study details include: * The total study duration per participant will be up to 42 days, including up to 21 days for screening and approximately 21 days from institutionalization to the end of study (EOS). * Institutionalization is mandatory until the activities on D5 have been completed. * Each participant will receive a single dose of venglustat. * For hepatically impaired participants there will be a screening visit, a multi-day institutionalization visit, and 7 site visits after D5 discharge, including the end of study (EOS) visit. * For healthy volunteers there will be a screening visit, a multi-day institutionalization visit and 3 site visits after D5 discharge, including the end of study (EOS) visit.

Hepatic Function Abnormal

Sanofi26 participantsStarted Jan 2023

Rialto, California, United States • Miami, Florida, United States • Saint Paul, Minnesota, United States +3 more locations

COMPLETEDPhase 1126 miles

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

NCT04344795

This is a first-in-human Phase 1a/1b, multicenter, open-label, dose-escalation, dose and schedule optimization, and expansion study of TPST-1495 as a single agent and in combination with pembrolizumab to determine its maximum tolerated dose (MTD) and or recommended Phase 2 dose (RP2D), safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity in subjects with advanced solid tumors. Subjects with all histologic types of solid tumors are eligible for the escalation and dose-finding portions of the study. However, the preferred tumor types for enrollment are colorectal cancer (CRC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial cancer, endometrial cancer, and gastroesophageal junction (GEJ) or gastric adenocarcinoma. Enrollment in the expansion cohorts is limited to the following tumor types: endometrial, SCCHN, CRC, and a basket cohort in subjects selected for an activating mutation in PIK3Ca.

Solid TumorColorectal CancerNon Small Cell Lung Cancer+6 more

Tempest Therapeutics89 participantsStarted May 2020

Aurora, Colorado, United States • Baltimore, Maryland, United States • Springfield, Massachusetts, United States +8 more locations

Active Not RecruitingPhase 1/2127 miles

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

NCT01012817

This phase I/II trial studies the side effects and best dose of veliparib and topotecan hydrochloride and to see how well they work in treating patients with solid tumors, ovarian cancer that has come back or does not respond to treatment, or primary peritoneal cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib with chemotherapy may kill more tumor cells.

Metastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+2 more

National Cancer Institute (NCI)88 participantsStarted Nov 2009

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Sacramento, California, United States +12 more locations

Active Not Recruiting151 miles

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

NCT05991323

This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with prurigo nodularis (PN). The primary objective of this study is to comprehensively characterize the real-world usage of dupilumab for the management of PN. In addition to this, the study aims to achieve several secondary objectives, including a detailed assessment of the medical history, socio-demographic and disease characteristics of dupilumab-treated PN patients, as well as the evaluation of the long-term real-world effectiveness of dupilumab therapy for PN.

Prurigo Nodularis

Sanofi100 participantsStarted Dec 2023

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Fremont, California, United States +46 more locations

COMPLETEDPhase 2159 miles

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

NCT05358821

The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.

Huntington Disease

Supernus Pharmaceuticals, Inc.69 participantsStarted May 2022

Birmingham, Alabama, United States • Los Alamitos, California, United States • Englewood, Colorado, United States +11 more locations

COMPLETEDPhase 2159 miles

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

NCT05107128

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.

Huntington's Disease

Supernus Pharmaceuticals, Inc.189 participantsStarted Jan 2022

Little Rock, Arkansas, United States • La Jolla, California, United States • Los Angeles, California, United States +46 more locations

COMPLETEDNA159 miles

PROmotion of COVID-19 BOOSTer VA(X)Ccination in the Emergency Department - PROBOOSTVAXED

NCT06156215

The goal of this cluster randomized clinical trial is to test the efficacy of messaging interventions to increase booster vaccine uptake in adults in the emergency department(ED). The main question\[s\] and goals of this study are: * does the intervention of vaccine messaging increase booster vaccine uptake at 30 days post ED visit? * does the intervention of asking about vaccine acceptance increase booster vaccine uptake at 30 days post ED visit? * considering recent national changes to funding and availability of updated vaccines, the investigators will examine the effects of these changes on vaccine acceptance and uptake in ED populations. Specifically, they will stratify EDs and ED patients according to the ED availability of vaccines, and they will also examine whether costs and availability of vaccines are a deterrent to patient acceptance and uptake of vaccines

University of California, San Francisco919 participantsStarted Jan 2024

San Francisco, California, United States • San Francisco, California, United States • Durham, North Carolina, United States +4 more locations

TERMINATEDPhase 2627 miles

A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

NCT05814016

The main aim is to see if danavorexton can help improve people's breathing in the recovery room after abdominal surgery.

Takeda41 participantsStarted May 2023

Sheffield, Alabama, United States • Phoenix, Arizona, United States • La Jolla, California, United States +16 more locations

COMPLETEDPhase 1685 miles

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

NCT05426174

This is a Phase I, first-in-human, randomized, modified double-blind, active-controlled, dose-escalation study to assess the safety and immunogenicity of up to 3 dose levels of mRNA NA vaccines, administered as a single IM injection in healthy adults aged 18 years and older. Two age groups, 18 to 64 years and ≥65 years, will be included in this study.

Influenza ImmunizationHealthy Volunteers

Sanofi Pasteur, a Sanofi Company233 participantsStarted Jun 2022

Huntsville, Alabama, United States • Phoenix, Arizona, United States • San Diego, California, United States +3 more locations

COMPLETEDPhase 3698 miles

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

NCT03596866

Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this study, participants will be people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to learn if brigatinib stops the tumors from growing, or if the tumors have shrunk or disappeared, compared to a medicine called alectinib. At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 treatments by chance: * Brigatinib tablets * Alectinib capsules All participants will take brigatinib or alectinib at about the same time every day. They will continue with treatment throughout the study unless their cancer gets worse, they have side effects from the treatment, they leave the study for certain reasons, or the study is stopped. After stopping treatment, participants will visit the study clinic for a check-up 30 days later.

ALK+ Advanced NSCLC

Takeda248 participantsStarted Apr 2019

Whittier, California, United States • Athens, Georgia, United States • Albany, New York, United States +111 more locations

Active Not RecruitingPhase 2/3725 miles

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency

NCT05397665

This study is designed to assess the efficacy and safety of AT-007 treatment in patients with SORD Deficiency. This randomized, double-blind study will assess the effect of AT-007 compared to Placebo in SORD Deficiency in patients for up to 24 months.

Hereditary Neuropathy Caused by SORD Deficiency

Applied Therapeutics, Inc.56 participantsStarted Jan 2022

Aurora, Colorado, United States • Coral Gables, Florida, United States • Iowa City, Iowa, United States +7 more locations

TERMINATEDPhase 3863 miles

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

NCT05220397

The purpose of this research is to see if a dose of the Janssen Ad26.CoV2.S vaccine effects the immune protection in individuals who have had a kidney transplant and two or three doses of mRNA vaccine (Pfizer and/or Moderna vaccines).

Kidney Transplant Recipient

Mark Stegall468 participantsStarted Apr 2022

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States

COMPLETEDPhase 2926 miles

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

NCT04476017

The primary purpose of this two-part study was to evaluate the safety and tolerability of SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with Parkinson's disease mild cognitive impairment (PD-MCI).

Parkinson DiseaseCognitive Dysfunction

Supernus Pharmaceuticals, Inc.18 participantsStarted Jul 2020

Long Beach, California, United States • Port Charlotte, Florida, United States • West Palm Beach, Florida, United States +1 more locations

SUSPENDEDPhase 1/21232 miles

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders

NCT02946658

Chronic Obstructive Pulmonary Disease (COPD) is a lung-related disorder that is characterized by long-term, often progressive state of poor airflow. Primary symptoms include low oxygen tension, shortness of breath, productive cough, and broncho-pulmonary inflammation and interference with oxygen-carbon dioxide exchange. Air pollution and tobacco smoking are felt to be the most common cause of these issues. Diagnostic testing is based on poor airflow measured by lung function studies and whose symptoms do not improve much with antiasthma bronchodilators. Study is an interventional study to document the safety and efficacy of use of AD-cSVF in chronic broncho-pulmonary disease groups.

Healeon Medical Inc100 participantsStarted Oct 2016

Stevensville, Montana, United States • Roatán, HN, Honduras

PreviousPage 142 of 649Next

Heart Diseasein Texas